David Ramsey, MD, PhD, MPH, outlines why patients with diabetes should undergo regular eye examinations.
Monitoring diabetic retinopathy can prevent irreversible vision loss, said David Ramsey, MD, PhD, MPH, an ophthalmologist and director of ophthalmic research at Lahey Hospital and Medical Center of Beth Israel Lahey Health. Ramsey presented research during an American Academy of Ophthalmology 2021 conference session called "Telehealth Encourages More Minority Patients With Diabetes to Return for In-Person Care During the COVID-19 Pandemic." Research coauthors included Karen Latulippe; Jeffrey L. Marx, MD; Shiyoung Roh, MD; Claudia C. Lasalle; Sidrah Anjum; and Ed Momplaisir.
Transcript
Why is it so important patients with diabetes receive eye examinations?
Diabetic retinopathy is the leading cause of vision loss among working-age Americans. Delivering eye care, examining patients with diabetes to monitor them for the development of diabetic retinopathy, and once it's developed, monitoring it to determine the point at which it needs treatment can not only prevent irreversible vision loss, but can actually help patients to recover vision once the effects of diabetic retinopathy have begun to take their effect on the retina. We have many different therapies available now, ranging from medications that can be administered into the eye to laser therapy, that have been shown not only to prevent blindness and allow more Americans to continue working, but even reverse the effects of diabetes and the age-associated toll that it takes on the visual system.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More